Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Vassiliki Papadimitrakopoulou
SWOG Cancer Research Network
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
627 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Fowler Family Center for Cancer Care
Jonesboro, Arkansas, United States
- University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
- Kaiser Permanente-Anaheim
Anaheim, California, United States
- Kaiser Permanente-Deer Valley Medical Center
Antioch, California, United States
- Sutter Auburn Faith Hospital
Auburn, California, United States
- Kaiser Permanente-Baldwin Park
Baldwin Park, California, United States
- Kaiser Permanente-Bellflower
Bellflower, California, United States
- Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, United States
- Mills-Peninsula Medical Center
Burlingame, California, United States
- Sutter Davis Hospital
Davis, California, United States
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Kaiser Permanente Hospital
Fontana, California, United States
- Kaiser Permanente-Fremont
Fremont, California, United States
- Washington Hospital
Fremont, California, United States
- Kaiser Permanente
Fresno, California, United States
- Saint Jude Medical Center
Fullerton, California, United States
- Kaiser Permanente - Harbor City
Harbor City, California, United States
- Kaiser Permanente-Irvine
Irvine, California, United States
- Uc San Diego Moores Cancer Center
La Jolla, California, United States
- City of Hope Antelope Valley
Lancaster, California, United States
- Loma Linda University Medical Center
Loma Linda, California, United States
- Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States
- Kaiser Permanente-Cadillac
Los Angeles, California, United States
- Los Angeles County-Usc Medical Center
Los Angeles, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Kaiser Permanente-Modesto
Modesto, California, United States
- Memorial Medical Center
Modesto, California, United States
- Palo Alto Medical Foundation-Camino Division
Mountain View, California, United States
- Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California, United States
- Sutter Cancer Research Consortium
Novato, California, United States
- Kaiser Permanente-Oakland
Oakland, California, United States
- Saint Joseph Hospital - Orange
Orange, California, United States
- Kaiser Permanente - Panorama City
Panorama City, California, United States
- Feather River Cancer Center
Paradise, California, United States
- Eisenhower Medical Center
Rancho Mirage, California, United States
- Kaiser Permanente-Redwood City
Redwood City, California, United States
- Kaiser Permanente-Richmond
Richmond, California, United States
- Kaiser Permanente-Riverside
Riverside, California, United States
- Kaiser Permanente-Roseville
Roseville, California, United States
- Sutter Roseville Medical Center
Roseville, California, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 16 Jun 2014
- Primary completion
- 12 Jan 2015
- Completion
- 12 Oct 2016
- Last update posted
- 19 Mar 2020
- Registered enrollment
- 9
- Registry id
- NCT02926638
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.